Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

DP Petrylak, P Kantoff, NJ Vogelzang, A Mega… - The …, 2019 - Wiley Online Library
Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …

In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen

X Wang, D Ma, WC Olson, WDW Heston - Molecular cancer therapeutics, 2011 - AACR
Prostate-specific membrane antigen (PSMA) is a membrane protein that is overexpressed
manifold in prostate cancer and provides an attractive target for therapy. PSMA ADC is an …

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate …

DP Petrylak, NJ Vogelzang, GS Chatta, MT Fleming… - 2015 - ascopubs.org
144 Background: PSMA is a validated target that is overexpressed selectively on prostate
cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule …

Small molecule-based prodrug targeting prostate specific membrane antigen for the treatment of prostate cancer

X Wang, A Shirke, E Walker, R Sun, G Ramamurthy… - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …

Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts

VA DiPippo, WC Olson, HM Nguyen, LG Brown… - The …, 2015 - Wiley Online Library
BACKGROUND It is timely and important to develop new treatment modalities for advanced
prostate cancer, because even the newly FDA approved treatments, despite providing …

Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer

JD Murga, SM Moorji, AQ Han, WW Magargal… - The …, 2015 - Wiley Online Library
BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …

A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer …

DP Petrylak, DC Smith, LJ Appleman, MT Fleming… - 2014 - ascopubs.org
5023 Background: PSMA expression on prostate cancer cells provides a rationale for ADC
therapy. PSMA is a clinically validated target. PSMA ADC is a fully human antibody to PSMA …

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen

D Ma, CE Hopf, AD Malewicz, GP Donovan… - Clinical Cancer …, 2006 - AACR
Prostate-specific membrane antigen (PSMA) is the prototypic cell-surface marker of prostate
cancer and provides an attractive target for monoclonal antibody (mAb) targeted therapies …

[PDF][PDF] Antibody-drug conjugates targeting prostate-specific membrane antigen

WC Olson, RJ Israel - Front Biosci (Landmark Ed), 2014 - article.imrpress.com
Cell-surface markers of prostate cancer 3. PSMA as a target for cancer therapy 4. Antibody-
drug conjugate chemistries 5. Preclinical findings 5.1. PSMA ADC 5.2. MLN2704 5.3 …

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in …

DP Petrylak, NJ Vogelzang, K Chatta… - The …, 2020 - Wiley Online Library
Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic
and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA …